Kiniksa Pharmaceuticals International, plc
Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) is a biopharmaceutical company that develops and commercializes therapies for diseases with unmet medical need, with a focus on cardiovascular conditions. Its commercial product, ARCALYST, is an interleukin-1α and interleukin-1β inhibitor approved in the United… From the company’s description.
Over the twelve months to Sep 30, 2026, Kiniksa Pharmaceuticals International, plc reported revenue of $945.96M, up 58.2% from a year earlier, and net income of $109.57M. Its operating margin was 13.8%, and operations generated $198.84M in cash. In fiscal 2025, it reported revenue of $677.56M, up 60.1% from fiscal 2024, and net income of $59.01M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Kiniksa Pharmaceuticals International, plc does
In the company’s own words
Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) is a biopharmaceutical company that develops and commercializes therapies for diseases with unmet medical need, with a focus on cardiovascular conditions. Its commercial product, ARCALYST, is an interleukin-1α and interleukin-1β inhibitor approved in the United States for recurrent pericarditis, certain cryopyrin-associated periodic syndromes and deficiency of interleukin-1 receptor antagonist. The company sells ARCALYST in the United States through specialty pharmacies and shares profits and third-party proceeds with Regeneron; it has also licensed development and commercialization rights in parts of Asia to Huadong. Kiniksa is developing KPL-387, an antibody targeting interleukin-1 receptor 1, for recurrent pericarditis, and KPL-1161, a related preclinical candidate. It is exploring strategic alternatives for abiprubart, an investigational antibody previously studied in autoimmune diseases. ARCALYST is its only commercial product, and recurrent pericarditis is its primary commercial focus; the U.S. patient population receiving treatment is estimated at approximately 40,000.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- LONDON
- Fiscal year end
- December
- CIK
- 1730430
- SIC
- 2834
Financial performance, year by year
Fiscal 2018–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Kiniksa Pharmaceuticals International, plc — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Kiniksa Pharmaceuticals International, plc’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Kiniksa Pharmaceuticals International, plc and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Kiniksa Pharmaceuticals International, plc's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Kiniksa Pharmaceuticals International, plc's last four quarterly filings that the numbers alone won't show?”